Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

The Wave

Senatein sessionHousein session
Refreshed 1 min ago
News

STAT+: 7 burning questions about the FDA’s post-Overton future

Why it’s here: Covers the White House withdrawal of the FDA commissioner nominee, user fee reauthorization, and FDA biotech competition with China, all federal biotechnology policy within scope.

Trace across the board

Item

  1. 3d agoSTATSTAT+: 7 burning questions about the FDA’s post-Overton futureSTAT's Readout Loud podcast episode covers the Trump administration withdrawing Heidi Overton's FDA commissioner nomination, the FDA's rejection of Summit Therapeutics and Akeso's lung cancer drug, and STAT's new index ranking China's largest drugmakers.
    4 articles · 2 outlets
    1. 4d agoSTATSTAT+: White House pulls nomination of Heidi Overton to lead FDA
    2. 4d agoYahooPickupWhite House pulls FDA nominee Heidi Overton after wavering support from Senate Republicans
    3. 3d agoSTATSTAT+: 7 burning questions about the FDA’s post-Overton future
    4. 2d agoSTATEarliestFDA’s search for a new leader, and China’s largest drugmakers
    Biotech66 linked

Coverage

2 outlets · first seen 4d ago

Connected

25 links

About

  • Food and Drug Administration
  • Prescription Drug User Fee Act
  • Bernie Sanders
  • Heidi Overton
  • Kyle Diamantas

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

STAT+: 7 burning questions about the FDA’s post-Overton future — The Wave